TriNetX data analysis demonstrated that SGLT2 inhibitors significantly lowered the risk of heart failure worsening and AF in patients with cancer treatment-related cardiac dysfunction [49], which is tied to pharmacological actions of attenuating oxidative stress and stimulating mitochondrial biogenesis [50,51]. This evidence concerns the gene SLC5A2 and heart failure.